Susquehanna International Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Susquehanna International Group’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-53,276	Closed	-$1.23M	–	13239
2020 Q4	$1.23M	Buy	+53,276	New	+$675K	﹤0.01%	6222

Susquehanna International Group's PRVL Position: Q1 2021 in Review

Susquehanna International Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 53,276 shares — an estimated $1.23M sold.

Susquehanna International Group first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $1.23M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Susquehanna International Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Susquehanna International Group sold 53,276 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $1.23M.
Susquehanna International Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Susquehanna International Group's Prevail Therapeutics Inc. Common Stock position peaked at $1.23M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Susquehanna International Group's 13F filing for Q1 2021, filed 17 May 2021.